Business Standard

Saturday, December 21, 2024 | 06:02 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

'Almost a sure bet': Manufactured antibodies promise coronavirus treatment

Development of monoclonal antibodies to target the virus has been endorsed by leading scientists

CORONAVIRUS
Premium

Unlike vaccines, which activate the body's own immune system, the impact of infused antibodies eventually dissipates.

Reuters
As the world awaits a Covid-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus.

Development of monoclonal antibodies to target the virus has been endorsed by leading scientists. Anthony Fauci, the top US infectious diseases expert, called them "almost a sure bet" against Covid-19.

When a virus gets past the body's initial defenses, a more specific response kicks in, triggering production of cells that target the invader. These include antibodies that recognize and lock onto

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in